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Abstract
Background:  Despite its direct connection to the nasopharynx which harbors otitis media
pathogens as part of its normal flora, the middle ear cavity is kept free of these bacteria by as yet
unknown mechanisms. Respiratory mucosal epithelia, including those of the middle ear and
eustachian tube, secrete antimicrobial effectors including lysozyme, lactoferrin and β defensins-1
and -2. To elucidate the role of these innate immune molecules in the normal defense and
maintenance of sterility of respiratory mucosa such as that of the middle ear, we assessed their
effect on the respiratory pathogens nontypeable Haemophilus influenzae (NTHi) 12, Moraxella
catarrhalis 035E, and Streptococcus pneumoniae 3, and 6B.
Methods: Two assay methods, the radial assay and the liquid broth assay, were employed for
testing the antimicrobial activity of the molecules. This was done in order to minimize the
possibility that the observed effects were artifacts of any single assay system employed. Also,
transmission electron microscopy (TEM) was employed to evaluate the effect of antimicrobial
innate immune molecules on OM pathogens. For the statistical analysis of the data, Student's t-test
was performed.
Results: Results of the radial diffusion assay showed that β defensin-2 was active against all four
OM pathogens tested, while treatment with β defensin-1 appeared to only affect M. catarrhalis. The
radial assay results also showed that lysozyme was quite effective against S. pneumoniae 3 and 6B
and was partially bacteriostatic/bactericidal against M. catarrhalis. Lysozyme however, appeared not
to affect the growth of NTHi. Thus, lysozyme seems to have a more pronounced impact on the
growth of the Gram-positive S. pneumoniae as compared to that of Gram-negative pathogens.
Lactoferrin on the other hand, enhanced the growth of the bacteria tested. The results of the radial
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assays were confirmed using liquid broth assays for antimicrobial activity, and showed that
lysozyme and β defensin-2 could act synergistically against S. pneumoniae 6B. Moreover, in the liquid
broth assay, β defensin-1 showed a modest inhibitory effect on the growth of S. pneumoniae 6B. As
assessed by ultrastructural analysis, lysozyme and β defensin-2, and to a much lesser extent, β
defensin-1, appeared to be able to cause damage to the bacterial membranes.
Conclusions: Here we report that lysozyme and the β defensins can inhibit the growth of clinical
isolates of otitis media pathogens – namely NTHi strain 12, S. pneumoniae strains 3 and 6B and M.
catarrhalis strain 035E – and cause ultrastructural damage to these pathogens. Moreover, we
demonstrate that lysozyme and β defensin-2 can act synergistically against S. pneumoniae. These
findings are consistent with the concept that secreted antimicrobial peptides and other
components of innate immunity constitute the first line of defense protecting host mucosal
surfaces, including the tubotympanal (eustachian tube and middle ear cavity) mucosa, against
pathogens.
Background
Otitis media (OM) is the most prevalent mucosal infec-
tious disease affecting young children, second only to the
common cold [1]. OM is also the major cause of conduc-
tive hearing loss among this group and the leading indica-
tion for antibiotic therapy [1]. OM results in 31 million
annual visits to physicians' offices and is estimated to
have a yearly cost exceeding $5 billion.
Most cases of OM are caused by three major pathogens: S.
pneumoniae (30–40%), nontypeable Haemophilus influen-
zae (NTHi, 30%) and M. catarrhalis (20%) [1,2]. These
organisms are also pathogens for sinusitis and chronic
obstructive pulmonary disease (COPD) [3]. In the past
three decades, there has been a dramatic worldwide
increase in antibiotic resistance in respiratory pathogens
[4,5]. This has resulted in a reduction of the number of
effective antibiotics for OM and has begun to pose a major
public health threat. There is, thus, an urgent need to
develop new and innovative non-antibiotic approaches to
prevent and manage this disease. To this end, it is imper-
ative to understand the mechanisms that defend the
tubotympanum (the middle ear and eustachian tube)
against invading pathogens and determine if the defense
mechanisms can be augmented to prevent or treat OM.
The pathogenesis of OM is multi-factorial with risk factors
such as delayed development of the adaptive immune sys-
tem, complement system abnormality, as well as other
environmental and genetic factors playing an important
role [6-10]. Although anatomic immaturity of the eus-
tachian tube and delayed development of systemic immu-
nity are considered to be the most important factors
underlying OM susceptibility among young children,
other factors may be of greater importance before the
adaptive immune system is fully matured [1,8]. For exam-
ple, in a study of children with recurrent acute otitis media
(rAOM), Prellner and colleagues showed that only 1/3 of
two-year-old children with rAOM had significantly lower
levels of antibodies against the pneumococcal capsular
type 19F. This suggests that factors other than circulating
antibody titers affect susceptibility to rAOM [8]. One
group of factors that may be of particular relevance to OM
susceptibility consists of the innate immune molecules,
including the defensins, lysozyme and lactoferrin [11-16],
as well as the pathogen recognition receptors such as the
toll-like receptors (TLR) [3,17]. Many studies have dem-
onstrated the presence of lysozyme and lactoferrin in
chronic middle ear effusion [18-21] and recent work has
shown that TLR-2, TLR-4, the defensins, lysozyme and
lactoferrin are expressed, albeit at different levels, in nor-
mal middle ear epithelial cells, as well as in those cells
from patients with chronic otitis media with effusion
(OME) [3,17,22-24]. The exact role however, that these
molecules play in normal mucosal defense and mainte-
nance of tympanic cavity sterility as well as in the OM sus-
ceptibility has not yet been clearly elucidated.
Here we report that lysozyme and the β defensins can
inhibit the growth of clinical isolates of otitis media path-
ogens, namely, NTHi 12, M. catarrhalis 035E, and S. pneu-
moniae  3, and 6B and cause ultrastructural damage to
these pathogens. Moreover, we demonstrate that lys-
ozyme and β defensin-2 can act synergistically against S.
pneumoniae.
Methods
Bacteria
All bacteria used in this study were clinical isolates.
NTHi and M. catarrhalis
Stocks of NTHi 12 (obtained from Dr. Steve Barenkamp,
St. Louis University, School of Medicine) and M. catarrha-
lis 035E (obtained from Dr. Eric Hansen, University of
Texas, Southwestern Medical Center) were maintained at
-80°C. The bacteria were plated on chocolate agar and
incubated overnight at 37°C in 5% CO2. A single colony
was used to inoculate 10 ml of brain heart infusion (BHI,BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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Becton Dickinson, Cockeysville, MD), supplemented with
hemin (10 µg/ml, Sigma, St. Louis, MO) and nicotina-
mide adenine dinucleotide (NAD, 10 µg/ml, Sigma, St.
Louis, MO), and allowed to grow overnight. In the morn-
ing, 1/10 volume of the overnight culture was transferred
to fresh medium and incubated for 3 hours. The subcul-
ture was then washed twice with 10 mM sodium phos-
phate and the optical density (O.D.) at 620 nm was
determined.
S. pneumoniae
For the S. pneumoniae 3 and 6B (obtained from Amecrican
Type Culture Collection, ATCC), a 50 µl aliquot of the fro-
zen stock was thawed on ice, added to 10 ml of Todd-
Hewitt broth (THB, Becton Dickinson, Cockeysville, MD)
and cultured overnight. One tenth of the volume of the
overnight culture was then transferred to fresh medium
and incubated for 3 hours. The subculture was then
washed twice with 10 mM sodium phosphate and the
O.D. at 620 nm was determined.
Testing of antimicrobial activity
Radial assay
The radial assay method of Lehrer and coworkers was
used, with minor modifications [39]. The subcultured
bacteria (4 × 106 CFU/10 ml underlay gel for NTHi and M.
catarrhalis and 106 CFU/10 ml underlay gel for S. pneumo-
niae) were mixed with melted underlay agarose medium
at 42°C (0.1X culture broth – BHI for NTHi and M.
catarrhalis and THB for S. pneumoniae- 10 mM sodium
phosphate, 0.8% low electroendosmosis (EEO)-type aga-
rose) and poured into 8 cm × 8 cm square petri plates. The
gel was allowed to solidify in the petri plates and wells
were punched out with a cork borer (4 mm, VWR Scien-
tific, West Chester, PA). The antimicrobial peptides and
proteins, human milk lysozyme (Sigma, St. Louis, MO),
human milk apo-lactoferrin (0.03% iron content, Sigma,
St. Louis, MO), human β defensin-1 and human β
defensin-2 (Peptides International, Louisville, KY), were
dissolved in 0.01% acetic acid/0.1% bovine serum albu-
min (Sigma, St. Louis, MO) and 4 µl was added to each
well. The plates were then incubated for 3 hours at 37°C
in the 5% CO2 incubator. They were next overlaid with the
overlay agarose medium (0.5X culture broth, 10 mM
sodium phosphate, 0.8% low EEO-type agarose) and cov-
ered. The plates were then allowed to incubate overnight
at 37°C in a 5% CO2. The diameter of the zones of inhi-
bition produced by each of the antimicrobial molecules
against the OM pathogens (NTHi, M. catarrhalis and S.
pneumoniae) was then measured in three separate experi-
ments and the mean and standard deviation were calcu-
lated. To analyze the salt dependency of the activity of
antimicrobial molecules against OM pathogens, NaCl was
added to the underlay gel solution to obtain a final NaCl
concentration of 100 mM.
Antibacterial liquid broth assay
For the antibacterial liquid broth assays, 1/10 of the vol-
ume of each overnight culture was transferred to fresh
medium and allowed to grow to mid-log phase. The bac-
teria were then exposed to various concentrations of lys-
ozyme, β defensin-1, β defensin-2 or a combination of the
lysozyme and β defensin-2 molecules for 3 h at 37°C. Cell
viability was measured by plating several dilutions and
counting the number of colonies after and overnight incu-
bation. The assay was done in triplicate for each concen-
tration of test molecules.
Statistical analysis
Student's t-test was used to perform statistical analysis of
the data.
Electron microscopy
Transmission electron microscopy (TEM) was employed
to evaluate the effect of antimicrobial innate immune
molecules on OM pathogens. The bacterial cultures
treated with antimicrobial proteins or peptides for 30
minutes (β defensin-1 treatment was for 3 hours) were
mixed with an equal volume of 5% buffered glutaralde-
hyde (pH 7.4) and centrifuged (5000 × g, for 20 minutes).
The bacterial pellets were left in the fixative at 4°C for 2
hr, post-fixed in 2% osmium tetroxide, dehydrated in
graded ethanol and embedded in Eponate 12 (Ted Pella,
Inc. Redding, CA). Thin sections (70 µm) were mounted
on coated specimen grids, contrasted with uranyl acetate
and lead citrate and examined in a transmission electron
microscope (CM120 BioTwin, FEI-Philips, Hillsboro, OR)
operating at 80 kV.
Results
Antimicrobial activity of innate immune molecules against 
OM pathogens
We tested the bacteriostatic/bactericidal effects of the
innate immune molecules on four clinically relevant otitis
media pathogens: NTHi 12, M. catarrhalis 035E and S.
pneumoniae 3 and 6B. Two assay methods, the radial assay
and the liquid broth assay, were employed for testing the
antimicrobial activity of the molecules. This was done in
order to minimize the possibility that the observed effects
were artifacts of any single assay system employed.
Radial assay
The results of the radial assay indicated that the treatment
of the bacteria with lysozyme resulted in a visible inhibi-
tion of the growth of M. catarrhalis and S. pneumoniae 3
and 6B (Figure 1A and Table 1). This effect was seen at
concentrations of 12.5 mg/ml (50 µg of the protein per
well) and higher. There appeared to be a dose-dependent
increase in the effect of lysozyme on the growth of S. pneu-
moniae and M. catarrhalis, although the dose dependence
of the effect was not as apparent with the latter pathogen.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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Lysozyme appeared not to affect the growth of NTHi (Fig-
ure 1A and Table 1). Thus, lysozyme appears to have a
more pronounced impact on the growth of the Gram-pos-
itive S. pneumoniae compared to the Gram-negative path-
ogens (Figure 1A and Table 1).
It should be noted that the concentration of lysozyme
decreases as it diffuses radially into the three-dimensional
gel matrix. Moreover, the concentration of lysozyme
ranges from 1.1 mg/ml in serous middle ear effusions to
3.71 mg/ml in mucoid in middle ear effusions [20]. Thus,
once dilution as a result of diffusion is taken into account
the amounts used in our assays are likely to give near
physiologic levels of this protein in the gel matrix.
Apo-lactoferrin treatment did not inhibit bacterial
growth, and appeared to result in an enhancement of the
growth of all bacteria tested at 40 µg dosage (Figure 1B
and Table 1).
Treatment with β defensin-1 was effective only against M.
catarrhalis and only at the high dose (10 µg). In contrast,
β defensin-2, at 4 µg and 10 µg, significantly inhibited the
growth of all four bacterial types (Figure 1B and Table 1).
The 40 µg dose of β defensin-2 was not tested because the
effects were already observable at the lower doses. Like-
wise, because β defensin-1 showed an effect against M.
catarrhalis  at 10 µg, a higher dose was not tested. M.
catarrhalis 035E was most susceptible to β defensin-2, fol-
lowed by NTHi 12, S. pneumoniae 3 and S. pneumoniae 6B.
Radial inhibition assay results demonstrating the effect of innate immune molecules on otitis media pathogens Figure 1
Radial inhibition assay results demonstrating the effect of innate immune molecules on otitis media patho-
gens. Representative radial inhibition assay for the measurement of the activity of innate immune molecules against NTHi 12, 
M. catarrhalis 035E (M cat), S. pneumoniae 3 (Sp 3) and S. pneumoniae 6B (Sp 6B). Panel A shows the results of testing three 
doses (50 µg, 100 µg and 200 µg) of human lysozyme (Lz) against the bacteria. Panel B shows the results of testing the lactof-
errin (Lf) and the defensins against the bacteria. Three doses (4 µg, 10 µg and 40 µg) of human lactoferrin (Lf) were tested, as 
were two doses (4 µg and 10 µg) each of human β defensin-1 (hBD-1) and β defensin-2 (hBD-2). Each dose was delivered in a 
total volume of 4 µl. The control well received only solvent (0.01% acetic acid). The diameter of the inhibition zone was meas-
ured and averaged in three separate experiments.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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In order to test the effect of high salt concentration on the
effectiveness of the antimicrobial molecules, NaCl was
added to the gel to obtain a final concentration of 100
mM. As shown in Table 2, 100 mM salt completely
blocked the growth inhibitory effect of lysozyme and β
defensin-1 against all bacteria tested. It also blocked the
effect of β defensin-2 against S. pneumoniae 3 and S. pneu-
moniae  6B. High salt concentration however, did not
inhibit the activity of β defensin-2 against NTHi and M.
catarrhalis, although it did result in a reduction of this
effect.
Antimicrobial liquid broth assay
The results of the radial assays were confirmed by per-
forming liquid broth antimicrobial assays using lysozyme
and  β defensin-2. Because of the robust antimicrobial
activity of the two molecules against S. pneumoniae 3 and
6B, we chose one of these, 6B, as a test organism to vali-
date the result of the radial assay. As shown in Figure 2A,
1 µg/ml of β defensin-2 did not demonstrate any signifi-
cant antimicrobial activity against S. pneumoniae 6B, while
at concentrations of 2.5 µg/ml and 5 µg/ml, it inhibited
growth by 80% and 95%, respectively. At a concentration
Table 1: Measurements of the effect of human lysozyme (hLz), lactoferrin (hLf), β defensin-1 (HBD-1) and β defensin-2 (HBD-2) on the 
growth of otitis media pathogens, using the radial inhibition assay.
Bacteria
Molecule Total amount of protein/peptide added 
(in a total volume of 4 µl)
NTHi M. catarrhalis S. pneumoniae 3 S. pneumoniae 6B
hLz 50 µg - 4.6 ± 0.4 (P) 6.2 ± 0.7 (C) 6.7 ± 0.9 (C)
100 µg - 5.6 ± 0.7 (P) 7.2 ± 0.5 (C) 7.4 ± 0.6 (C)
200 µg - 6.2 ± 0.5 (P) 7.7 ± 0.6 (C) 8.2 ± 0.7 (C)
hLf 4 µg ----
10 µgE - E -
40 µg EEEE
HBD-1 4 µg ----
10 µg - 7.7 ± 0.6 (P) - -
40 µg N DN DN DN D
HBD-2 4 µg 9.7 ± 2.5 (C) 11.7 ± 0.6 (C) 8.7 ± 1.5 (C) 8.7 ± 1.2 (C)
10 µg 12.3 ± 2.9 (C) 14.7 ± 0.6 (C) 10 ± 1.3 (C) 10.7 ± 1.5 (C)
40 µg N DN DN DN D
Diameter (mm) of the inhibition zone (average of 3 separate experiments ± SD) caused by the different concentrations of the antimicrobial 
molecules is given in the column below each pathogen. -: No effect; E: Enhanced growth; C: Complete inhibition; P: Partial inhibition; ND: Not done
Table 2: Measurements of the effect of 100 mM NaCl on the inhibition of the growth of otitis media pathogens by human lysozyme 
(hLz), lactoferrin (hLf), β defensin-1 (HBD-1) and β defensin-2 (HBD-2), using the radial inhibition assay.
Bacteria
Molecule Total amount of protein/peptide added 
(in a total volume of 4 µl)
NTHi M. catarrhalis S. pneumoniae 3 S. pneumoniae 6B
hLz 4 µg- - --
10 µg- - --
40 µg- - --
hLf 4 µg- - --
10 µg- - --
40 µg- - --
HBD-1 4 µg- - --
10 µg- - --
40 µg N DN DN DN D
HBD-2 4 µg 8.8 ± 1.0 (C) 9.0 ± 0.7 (C) - -
10 µg 11.3 ± 0.3 (C) 11.0 ± 0.7 (C)
40 µg N DN DN DN D
Diameter (mm) of the inhibition zone (average of 3 separate experiments ± SD) caused by the different concentrations of the antimicrobial 
molecules is given in the column below each pathogen. -: No effect; ND: Not doneBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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of 10 µg/ml, β defensin-2 completely inhibited the growth
of the bacteria. Beta defensin-1, on the other hand, did
not have a significant growth inhibitory effect at concen-
trations of 1 and 5 µg/ml, but inhibited the growth of S.
pneumoniae 6B by 25% at a concentration of 10 µg/ml.
Lysozyme also had a significant impact on bacterial
growth and at a concentration of 1 mg/ml resulted in a
70% inhibition of growth (Figure 2A). As shown in Figure
2B, a combination of β defensin-2 (1 µg/ml or 2.5 µg/ml)
and lysozyme (1 mg/ml) appeared to have a significant
synergistic effect and resulted in 95–100% inhibition of
bacterial growth.
The compatibility of the results obtained by the two assay
methods suggests that the radial assay, which is simpler to
perform than the liquid broth assay, is indeed a suitable
methodology for studying the antimicrobial activity of
innate immune molecules.
Ultrastructural changes in OM pathogens after treatment with 
lysozyme and β defensin-2
Ultrastructural analysis of NTHi 12, S. pneumoniae 3, S.
pneumoniae 6B and M. catarrhalis treated in solution with
the antimicrobial molecules revealed that changes
occurred in the bacteria following exposure to β defensin-
2 or lysozyme. The morphology of the untreated NTHi is
shown in Figure 3A. Figures 3B and 3C show the
morphology of NTHi treated with 10 µg/ml β defensin-2
for 30 minute, and 1 mg/ml of human milk lysozyme for
30 minute, respectively. It should be noted that lysozyme,
at concentrations lower than 1 mg/ml, had no observable
effect on the ultrastructure of the bacteria (data not
shown). In the presence of β defensin-2 or lysozyme,
NTHi show blebbing of the membranes with extrusion of
the cytoplasmic contents into the blebs (Figures 3B and
3C). The percentage of profiles showing membrane "bleb-
bing" was estimated by examination of approximately
100 bacterial profiles using systematic random sampling
methods [25]. With β defensin-2 treatment, at least 30%
of the bacteria showed signs of membrane damage, while
with lysozyme only 5% of the bacteria showed blebbing.
NTHi, incubated in liquid broth alone for 30 min, showed
blebbing in approximately 5% of the cases. This low inci-
dence of blebbing in the untreated bacteria suggests that
the observed changes in treated bacteria were not fixation
Liquid broth assay results demonstrating the susceptibility of S. pneumoniae to lysozyme and the β defensins Figure 2
Liquid broth assay results demonstrating the susceptibility of S. pneumoniae to lysozyme and the β defensins. 
Antibacterial liquid broth assays for the measurement of the activity of lysozyme (Lz) and β defensins-1 and -2 (HBD1 and 
HBD2), alone (A) and in combination (B) (Lz+HBD2), against S. pneumoniae 6B (Sp 6B). The combination of Lz and HBD1 was 
not tested. The combination of lysozyme (1000 µg/ml) and β defensin-2 (1 µg/ml or 2.5 µg/ml) was significantly more effective 
than lysozyme (1000 µg/ml), or β defensin-2 (1 µg/ml or 2.5 µg/ml) alone. (P = 0.008 and 0.005, respectively, for the difference 
in the effect of the Lz-HBD2 combinations versus Lz (1 mg/ml) alone. P= 0.0007 and 0.03 for the difference in the effect of the 
Lz-HBD2 combinations versus 2.5 µg/ml of β defensin-2 alone). Four concentrations (1 µg/ml, 2.5 µg/ml, 5 µg/ml and 10 µg) of 
human β defensin-2 (HBD-2) and one concentration (1 mg/ml) of lysozyme (Lz) were tested against the bacteria – either alone, 
or in combination.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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Ultrastructural changes in OM pathogens treated with innate immune molecules Figure 3
Ultrastructural changes in OM pathogens treated with innate immune molecules. Panels A, B and C are electron 
micrographs showing the experimental results with NTHi. Untreated NTHi are shown in panel A. Bacteria were treated for 30 
minutes with β defensin-2 (10 µg/ml) (panel B), or with 1 mg/ml human milk lysozyme (panel C). Bar = 0.5 micron. Panels D, E 
and F show results of experiments with S. pneumoniae 3. Untreated bacteria are shown in panel D. Bacteria were treated for 
30 minutes with human β defensin-2 (10 µg/ml) (panel E), or with 1 mg/ml human milk lysozyme (panel F). Bar = 0.5 micron. 
Panels G, H and I show the results of experiments S. pneumoniae 6B. Untreated bacteria are shown in panel G. Bacteria treated 
for 30 minutes with human β defensin-2 (10 µg/ml) are shown in panel H and those treated for 3 hours with human β defensin-
1 (10 µg/ml) are shown in panel I. Bar = 0.5 micron. Panels J, K and L show experiments results with M. catarrhalis. Untreated 
bacteria are shown in panel J. Results of a 30-minute incubation with β defensin-2 are shown in panel K and those of a 30 
minute treatment of the bacteria with lysozyme are shown in panel L. Bar = 0.5 micron.BMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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artifacts. Also, the difference in the percentage of damaged
bacteria could account for the absence of lysozyme's
growth inhibitory effect on NTHi in the radial assay.
Treatment of S. pneumoniae 3 with β defensin-2 or lys-
ozyme also resulted in damage to the bacteria, although
the former molecule appeared to be much more potent.
The untreated bacteria are shown in Figure 3D, while Fig-
ures 3E and 3F show the effect of a 30 minute treatment
with β defensin-2 and lysozyme, respectively. As seen in
Figure 3E, treatment with β defensin-2 results in the dis-
ruption of the cell membrane and the lysis of the bacteria.
Although lysozyme had a similar effect, fewer bacteria
appear to be lysed, consistent with the results of the radial
assay.
Human β defensin-2 showed activity against S. pneumo-
niae 6B as well. A 30 minute treatment with β defensin-2,
resulted in damage to the cell membrane and condensa-
tion of the cytoplasmic material (Figure 3H). Attempts to
evaluate the ultrastructural effect of lysozyme on S. pneu-
moniae  6B were unsuccessful because the bacteria
appeared to have been fully lysed by lysozyme. Treatment
of S. pneumoniae 6B with 10 µg of human β defesnsin-1 for
3 hours had a relatively small effect on the ultrastructure
of the bacteria (Figure 3I). Based on the enumeration of
lysed S. pneumoniae 6B in a random sampling of multiple
electron micrographs, less than 6% of the bacteria
appeared to have been lysed by this treatment, consistent
with the modest reduction in growth observed in the solu-
tion assay (data not shown).
The effect of β defensin-2 or lysozyme on M. catarrhalis
was also tested. Untreated M. catarrhalis are shown in Fig-
ure 3J. As shown in Figure 3K, a 30 minute incubation of
M. catarrhalis with  β defensin-2 resulted in substantial
damage to the cells. Results of a 30 minute treatment of
the bacteria with lysozyme are shown in Figure 3L and
suggest that this treatment can also result in the formation
of blebs. Samples from later time points, however,
showed no evidence of blebs and, as expected, contained
more lysed bacteria (data not shown).
Discussion
Respiratory mucosal epithelia, including the epithelium
of the middle ear, paranasal sinuses and lung, serve as an
effective barrier against pathogen invasion and help to
maintain the sterility of these sites. Innate immune mole-
cules produced by the epithelial cells provide the host
with a constitutive or immediately-inducible defense sys-
tem that is capable of effectively dealing with the contin-
uous attacks of a variety of pathogens at the mucosal
epithelial surfaces. Under normal conditions, the middle
ear of humans and laboratory animals remains sterile,
although OM pathogens, which are part of the normal
nasopharyngeal flora, can reach the middle ear via the
eustachian tube [26]. Furthermore, non-inflamed tubal
and middle ear mucosa have been shown to contain rela-
tively few immunocytes [7,27]. These findings suggest
that the components of the innate immune system may be
important in the defense of the tubotympanum (middle
ear and eustachian tube). Furthermore, as the develop-
ment of adaptive immunity occurs in late childhood,
innate immune molecules are likely to play an especially
important role in protecting infants and young children
against OM pathogens. Consistent with the hypothesis
that innate immune molecules protect the tubotympa-
num during the neonatal and early postnatal periods,
Park and Lim [15] showed that the number of secretory
cells expressing lysozyme was similar in the epithelium
and glandular structures of the eustachian tube of both
adult and early post-natal animals. Innate immune mole-
cules may, however, also be important for keeping the
tubotympanum sterile later in life, by serving as a first line
of defense even after the adaptive immune system has
fully matured.
As little is known about the antimicrobial activity of
innate immune molecules against respiratory pathogens,
in the present study we analyzed the effect of lysozyme,
lactoferrin, β defensin-1 and β defensin-2 on the growth
of known OM pathogens. The bacteria used in the present
study were chosen on the basis of their clinical relevance
in OM and other respiratory infections. NTHi 12 and M.
catarrhalis 035E are middle ear effusion clinical isolates
that have been used extensively in vaccine studies [28],
while S. pneumoniae 6B and 3 are prevalent OM pathogens
and have been isolated from middle ear effusions in as
many as 18.7% and 8.7%, respectively, of children in the
US [29].
The results of our studies suggest that lysozyme, β
defensin-1 and β defensin-2 have activity against the
above pathogens. Moreover, lysozyme and β defensin-2
appeared to have a profound synergistic effect against S.
pneumoniae 6B. These results are consistent with our pre-
vious observations and suggest that alone, or in
combination, innate immune molecules can be effective
against several clinically relevant OM pathogens [13].
Of the four molecules tested in the radial inhibition assay,
β defensin-2 displayed the highest potency and was effec-
tive against all pathogens tested. These results were con-
firmed using the liquid broth assay and additionally
showed that β defensin-2 had a potent, dose-dependent
effect on the growth of S. pneumoniae, even at concentra-
tions as low as 2.5 µg/ml. Previous studies have shown the
LD90 of β defensin-2 (the dose that achieves 90% reduc-
tion of colony-forming units) to be between 4 and 10 µg/
ml for Gram negative bacteria and as high as 100 µg/mlBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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for Gram positive bacteria [30,31]. Other studies have
shown the minimal inhibitory concentrations of β
defensin-2 for E. coli to be between 4 and 62 µg/ml [32].
β defensin-2 levels in the saliva and gingival crevicular
fluid have been shown to be approximately 150 ng/ml
and 75–175 ng/ml, respectively [33]. The normal plasma
concentration of β defensin-2 has been shown to be in the
30 pg/ml range and its epidermal concentration is esti-
mated to be between 3.5–16 µM [31,32]. It should be
noted, however, that local production of β defensin-2 and
its secretion into the periciliary fluid underneath the
mucous blanket is likely to result in higher concentrations
of this molecule on mucosal surfaces protected by the
mucociliary system.
β defensin-2 is produced by epithelial cells following con-
tact with microorganisms, or exposure to cytokines such
as TNF-α and IL-1 [34,35]. It has been shown to exhibit
potent antimicrobial activity against Gram-negative bacte-
ria and Candida, but was less effective against Gram-pos-
itive  Staphylococcus aureus [36,37]. We recently showed
that β defensin-2 could inhibit the growth of NTHi [13].
Our observations were later confirmed by Starner and col-
leagues [38] who showed that β defensins-2 and 3 could
kill NTHi. β defensin-2 functions as a NF-kB target gene in
the middle ear epithelium and blocking NF-kB activation
inhibits the up-regulation of human β defensin-2 in
response to IL-1α stimulation or bacterial infection [24].
Although the effect of β defensin-2 on NTHi was consist-
ent with our previous results [13] and those obtained by
Starner and coworkers [38], to our knowledge, its effect on
M. catarrhalis and S. pneumoniae has not been previously
reported.
In contrast to β defensin-2, β defensin-1 had a relatively
minor impact on the growth of the respiratory pathogens.
β defensin-1 is not upregulated by inflammatory stimuli,
is predominantly expressed in the distal tubules of the
kidney and in the digestive and reproductive tracts and
serves as a defense molecule in the absence of inflamma-
tion [34,39-41]. Consistent with previous observations of
the antimicrobial activities of this molecule against Gram-
negative bacteria [36], β defensin-1 did show some activ-
ity against M. catarrhalis in the radial diffusion assay. In
the liquid broth assay however, it also showed activity
against S. pneumoniae and caused a 25% inhibition of the
growth of this bacterium. When the damage to the β
defensin-1 treated S. pneumoniae was assessed by electron
microscopy, it was seen that only a small fraction of the
bacteria (less than 6%) were affected by the treatment.
Such a modest effect is unlikely to be observable in the
radial diffusion assay, although, as our results demon-
strate, it is detectable in the liquid broth assay. Regardless,
the results of both assays indicate that relatively high con-
centrations of β defensin-1 may be required for its antimi-
crobial effects and are consistent with the idea that this
molecule may be acting in concert with other components
of the innate immune system in order to be most effective.
As expected, defensin molecules showed salt sensitivity
and were inhibited by 100 mM salt, as previously reported
[42]. But, as the defensins have been shown to display a
concentration-dependent resistance to salt inactivation
[43], we believe that they will be active in vivo where their
high local concentration in the periciliary fluid space will
be sufficient to overcome the salt effect despite the pres-
ence of physiological levels of NaCl.
Lysozyme is an important component of innate immunity
against pathogens at mucosal surfaces, including the mid-
dle ear, where it is produced by the secretory cells of the
epithelium, as well as by neutrophils and macrophages
[12,19,44-46]. In studies by Liu and coworkers [20] they
showed that chronic mucoid middle ear effusions con-
tained on average 3.71 mg/ml of lysozyme, while chronic
serous middle ear effusions contained 1.1 mg/ml of this
protein. Moreover, their results suggested that the major-
ity of the lysozyme produced did not come from recruited
macrophages and neutrophils, but from local sources
such as epithelial cells. The presence of lysozyme in serous
cells of the tubal glands and the secretory epithelial cells
[18] also suggests an important role for this molecule in
the defense of the tubotympanum against pathogens [21].
Lysozyme is a muramidase that cleaves the glycan back-
bone by catalyzing the hydrolysis of 1–4-glycosidic bonds
between N-acetylmuraminic acid and N-acetyl-D-glu-
cosamine, which are constituents of the cell walls of most
bacteria. The amount of lysozyme used in the liquid broth
(1 mg/ml) was not outside the physiological range as evi-
denced by the fact that concentration of lysozyme in
human milk is nearly 0.9 mg/ml [47]. In the radial diffu-
sion assay however, higher concentrations of lysozyme
(12.5, 25 and 50 mg/ml) were required in order to see an
effect. This is because, the radial assay, in contrast to the
liquid broth assay, is based on the diffusion of molecules,
thus translating into a lower concentration of lysozyme
per unit volume in the gel.
The results of the radial diffusion assay showed that lys-
ozyme had activity against both S. pneumoniae serotypes,
as well as against M. catarrhalis. Lysozyme however, was
not shown to cause any detectable inhibition in the
growth of NTHi, although lysozyme-treated NTHi did
show changes at the ultrastructural level. This apparent
disparity may be due to the fact that only a small fraction
(5%) of lysozyme-treated NTHi showed any sign of dam-
age. Thus, with 95% of the cells still undamaged, it is
unlikely that any inhibition of growth would have been
detectable in the radial assay. Consistent with the observa-
tions of Chun and Hancock [48], lysozyme also appearedBMC Infectious Diseases 2004, 4 http://www.biomedcentral.com/1471-2334/4/12
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to display salt sensitivity and its effect was inhibited by
100 mM salt. As with the defensins, we believe that high
local concentrations of lysozyme in the periciliary fluid
space may be able to overcome the inhibitory effect of
physiological levels of NaCl.
The results of the solution assay corroborated our radial
diffusion assay data and demonstrated that physiological
concentrations of lysozyme do indeed inhibit the growth
of S. pneumoniae 6B. Moreover, our results showed that
lysozyme and β defensin-2 act synergistically against this
pathogen.
Unlike the results obtained with lysozyme and the β
defensins, treatment of the four respiratory pathogens
with lactoferrin appeared to have a growth enhancing
effect using the current culture conditions. All four bacte-
ria tested had a positive growth response to lactoferrin,
with NTHi 12 and S. pneumoniae 3 showing a higher sen-
sitivity than the other two. This result, however, is not sur-
prising, as M. catarrhalis has been shown to be able to use
lactoferrin as an iron source for growth in vitro and S.
pneumoniae has been shown to specifically recognize and
bind human lactoferrin [49]. Moreover, other bacteria
have also been shown to be able to use lactoferrin for
growth. For example, when grown under iron starvation,
Neisseria meningitidis expresses receptors for transferrin
and lactoferrin in the outer membrane [50].
Lactoferrin is a proteolytic, iron-binding antimicrobial
glycoprotein found in the milk and exocrine secretions of
mammals and is released from neutrophilic granules dur-
ing inflammation [51,52]. It has been suggested that the
presence of lactoferrin (and lysozyme) in human milk
may be at least one reason why babies raised on breast
milk are more resistant to OM than their formula-fed
counterparts [10,53]. Although in the present study we
did not observe any antibacterial activity by lactoferrin
when tested alone, in our previous studies we showed that
in the solution assay this molecule could enhance the
effect of lysozyme and defensins against respiratory path-
ogens [13]. Consistent with our observations, Plaut and
colleagues have shown that although the proteolytic
activity of lactoferrin causes Hap-positive NTHi strains to
lose their ability to adhere to Chang epithelial cells, it
does not by itself affect the viability of the bacteria [54].
Moreover, by using apo-lactoferrin with a 0.03% iron con-
tent, we ruled out the possibility that the growth-enhanc-
ing effect of lactoferrin may be due to its saturation with
iron and thus its activity as an iron source for the bacteria.
Although it is currently not known if an in vivo deficiency
of innate immune molecules is a risk factor for OM, our
preliminary results with mice deficient in surfactant pro-
tein D (SP-D), suggest that it is (Lee et al., unpublished
data). Surfactant proteins A (SP-A) and D are members of
the collectin family of innate immune molecules and have
been reported to bind lipopolysaccharide (LPS), opsonize
microorganisms, enhance the clearance of lung pathogens
and inhibit the growth of Gram-negative bacteria [55]. As
part of our future studies, we plan to expand our in vivo
studies by studying OM susceptibility in SP-A knockouts
as well in knockouts of other innate immune molecules.
Conclusions
Our results demonstrate that innate immune molecules
such as lysozyme, β defensin-1 and β defensin-2 can
reduce the viability of major OM pathogens, perhaps by
disrupting their membrane integrity. Our results also
show that β defensin-2 and lysozyme can act synergisti-
cally against S. pneumoniae 6B, an important OM patho-
gen. The current findings appear to be consistent with
earlier observations of the effect of these molecules on
bacterial integrity [48,56,57]. We, therefore, suggest that
the innate immune molecules such as lysozyme and β
defensins-1 and -2 provide the first line of defense against
respiratory pathogens in the tubotympanum and may be
useful for treating otitis media as an adjunct to antibiotics.
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